---
title: "Looking for Dividend Aristocrats? These 3 Healthcare Stocks Deserve a Closer Look"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301412622.md"
description: "AbbVie, Johnson & Johnson, and Medtronic are highlighted as Dividend Aristocrats with over 25 years of consecutive dividend increases. These healthcare stocks offer defensive portfolio exposure and reliable income growth due to steady demand across economic cycles. The article emphasizes their status on the S&P 500 and notes AbbVie's specific focus on biopharmaceuticals and its 2.51% dividend yield."
datetime: "2026-10-09T14:28:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301412622.md)
  - [en](https://longbridge.com/en/news/301412622.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301412622.md)
generator: "portal-rs"
---

# Looking for Dividend Aristocrats? These 3 Healthcare Stocks Deserve a Closer Look

AbbVie (ABBV), Johnson & Johnson (JNJ), and Medtronic (MDT) are three healthcare companies with established dividend-growth records and deserve a closer look. All three stocks are Dividend Aristocrats, listed on the S&P 500 (SPX). This means all three have raised their dividends for at least 25 straight years.

Healthcare stocks are considered defensive because demand for medical treatments, devices, and healthcare services stays steady across economic cycles. As a result, these dividend-paying healthcare leaders offer investors a balance of defensive portfolio exposure and reliable growing income.

The TipRanks Dividend Aristocrats tool lets investors filter companies with at least 25 years of dividend increases by sector and market cap, and see yield, payout ratio, and recent payouts.

**1\. AbbVie (ABBV)** — AbbVie is a biopharmaceutical company that develops and sells prescription medicines for serious conditions, including immune disorders, cancer, brain conditions, eye diseases, and cosmetic care. Its main products include treatments like Skyrizi, Rinvoq, and Botox, which help the company grow as it transitions away from its former top-selling drug, Humira. AbbVie has a dividend yield of 2.51%.

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [MDT.US](https://longbridge.com/en/quote/MDT.US.md)

## Related News & Research

- [4,692 AbbVie Inc. $ABBV Shares Bought by Sax Wealth Advisors LLC](https://longbridge.com/en/news/301740286.md)
- [Johnson & Johnson $JNJ Stock Sold by Generate Investment Management Ltd](https://longbridge.com/en/news/301871404.md)
- [Learn Why The Bull Case For AbbVie (ABBV) Could Change Following Cancer Drug Designations](https://longbridge.com/en/news/301731782.md)
- [Johnson & Johnson Warns New Drug Deals Will Hit 2027 Earnings](https://longbridge.com/en/news/301732516.md)
- [Johnson & Johnson says long-term data boosts Icotyde for plaque psoriasis](https://longbridge.com/en/news/301420344.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**